| References: |
FRAX597 inhibits the proliferation of NF2-deficient schwannoma cells in culture and displayed potent anti-tumor activity in vivo, impairing schwannoma development in an orthotopic model of NF2. These studies identify a novel class of orally available ATP-competitive Group I PAK inhibitors with significant potential for the treatment of NF2 and other cancers. For the detailed information of FRAX 597, the solubility of FRAX 597 in water, the solubility of FRAX 597 in DMSO, the solubility of FRAX 597 in PBS buffer, the animal experiment (test) of FRAX 597, the cell expriment (test) of FRAX 597, the in vivo, in vitro and clinical trial test of FRAX 597, the EC50, IC50,and affinity,of FRAX 597, For the detailed information of FRAX 597, the solubility of FRAX 597 in water, the solubility of FRAX 597 in DMSO, the solubility of FRAX 597 in PBS buffer, the animal experiment (test) of FRAX 597, the cell expriment (test) of FRAX 597, the in vivo, in vitro and clinical trial test of FRAX 597, the EC50, IC50,and affinity,of FRAX 597, Please contact DC Chemicals. |
